Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $9.1 million.

  • Stoke Therapeutics' Cash from Investing Activities rose 13030.93% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.9 million, marking a year-over-year decrease of 3358.43%. This contributed to the annual value of -$107.5 million for FY2024, which is 20144.32% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Cash from Investing Activities is $9.1 million, which was up 13030.93% from -$148.5 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Cash from Investing Activities high stood at $67.3 million for Q3 2022, and its period low was -$148.5 million during Q2 2025.
  • Its 4-year average for Cash from Investing Activities is -$11.5 million, with a median of $10.0 million in 2024.
  • Per our database at Business Quant, Stoke Therapeutics' Cash from Investing Activities surged by 1597739.73% in 2023 and then crashed by 47608.32% in 2024.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Cash from Investing Activities stood at $22.5 million in 2022, then tumbled by 34.32% to $14.8 million in 2023, then plummeted by 94.46% to $819000.0 in 2024, then skyrocketed by 1010.38% to $9.1 million in 2025.
  • Its Cash from Investing Activities was $9.1 million in Q3 2025, compared to -$148.5 million in Q2 2025 and $13.6 million in Q1 2025.